The U.S. Food and Drug Administration (FDA) issued a label revision for Amivantamab (Rybrevant) on May 21, 2026, adding a new Boxed Warning. This significant update highlights serious risks including cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity, requiring healthcare providers to be aware of these critical safety considerations.
What this means
The implementation of a Boxed Warning on the Amivantamab (Rybrevant) label represents a critical update for all healthcare professionals involved in prescribing or administering the medication. This highest-level safety alert from the FDA underscores the potential for severe adverse effects, specifically cardiomyopathy, embryo-fetal toxicity, and pulmonary toxicity. Clinicians are now required to exercise heightened vigilance, conduct thorough patient assessments, and implement robust monitoring protocols to detect and manage these risks promptly. Furthermore, comprehensive patient counseling, particularly concerning the implications of embryo-fetal toxicity for patients of reproductive potential, becomes paramount to ensure informed decision-making and patient safety. This label change emphasizes the need for a careful benefit-risk assessment for each individual patient receiving Amivantamab.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA). The updated prescribing information, including the Boxed Warning, was made effective on May 21, 2026, and is accessible via the DailyMed database hosted by the National Library of Medicine (dailymed.nlm.nih.gov).